Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27140412 | 0.95 | PTPN11 (0.44) | PTPN11DDB1CRBNPDPK1VCP | |
| SCHEMBL23789478 | 0.82 | DDB1 (0.49) | PTPN11DDB1CRBNVCPKDM4E | |
| SCHEMBL29429210 | 0.79 | PTPN11 (0.46) | PTPN11DDB1CRBNPDPK1VCP | |
| SCHEMBL23177723 | 0.79 | PTPN11 (0.46) | PTPN11DDB1CRBNPDPK1VCP | |
| SCHEMBL29450030 | 0.78 | TRPV1 (0.40) | PDPK1KDM4EAAK1 | |
| SCHEMBL1322072 | 0.78 | PLCG1 (0.35) | PDPK1METAP1 | |
| SCHEMBL29145511 | 0.78 | TRPV1 (0.40) | PDPK1KDM4EAAK1 | |
| SCHEMBL31751664 | 0.76 | PTPN11 (0.42) | PTPN11DDB1CRBNPDPK1L3MBTL1 | |
| SCHEMBL27140539 | 0.76 | PTPN11 (0.45) | PTPN11DDB1CRBNVCPKDM4E | |
| SCHEMBL30759295 | 0.74 | PTPN11 (0.41) | PTPN11DDB1CRBNPDPK1VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | PTPN11 3767/4885DDB1 1330/4885CRBN 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.